Physical activity, especially walking, was linked to less fatigue and better quality of life for patients with colorectal cancer, particularly in early survivorship.
Andrea Eleazar, MHS
Advertisement
Articles by Andrea Eleazar, MHS
Xervyteg improved responses and was safe in steroid- and Jakafi-resistant acute graft-versus-host disease affecting the GI tract in a phase 3 trial.
Sac-TMT improved progression-free survival in patients with HR+/HER2– breast cancer.
Among patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma that is resectable, Imfinzi with FLOT improved survival.
Advertisement
Latest Updated Articles
Xervyteg Shows Strong Responses in Acute Graft-Versus-Host DiseasePublished: December 8th 2025 | Updated:
Advertisement
Advertisement
Trending on CURE
1
Given Months to Live, She’s Now a Five-Year Glioblastoma Survivor
2
Tecvayli With Darzalex Could Be ‘Truly Transformative’ in Multiple Myeloma
3
How CAN-3110 Works to Treat Glioblastoma
4
Cancer Five-Year Survival Rate Hits Record 70%, 2026 Report Shows
5